亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Dr Reddy’s Laboratories launches Redyx (remdesivir) in India

expresspharmaSeptember 18, 2020

Tag: Dr Reddy , Redyx , India , Remdesivir

Dr Reddy’s Laboratories announced the launch of Remdesivir, under a brand name Redyx in India. The launch is part of the licensing agreement with Gilead Sciences that grants Dr Reddy’s the right to register, manufacture and sell Remdesivir, a potential treatment for COVID-19, in 127 countries including India.

Dr Reddy’s Redyx is available in the strength of 100 mg vial.

M V Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories, said, “The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”

Previous:Scientists at University of Sheffield discover new drug to treat pancreatic cancer

Next:Neovascularization inhibitor sales will near $7 bn in diabetic retinopathy market in 2029: GlobalData

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service